PEDIATRICS Vol. 115 No. 4 April 2005, pp. 1030-1038 (doi:10.1542/peds.2004-2231)
A Multicenter, Randomized, Controlled Trial of Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress Syndrome
* James Cook University Hospital, Middlesbrough, United Kingdom
Hospital Antoine-Beclere, AP/HP, Paris, France
Hospital de Cruces, University of Basque Country, Barakaldo, Bilbao (Bizkaia), Spain
|| State University of New York, Stony Brook, New York
¶ Poznan University of Medical Sciences, Poznan, Poland, and Polish Mother's Memorial Hospital Research Institute, Lódz, Poland
# Semmelweis Egyetem, Budapest, Hungary
** Sharp Mary Birch Hospital for Women, San Diego, California
Hospital General Gregorio Marañon, Madrid, Spain
Discovery Laboratories, Inc, Doylestown, Pennsylvania
|||| Boston University, Boston, Massachusetts
Background. Available therapeutic surfactants are either animal-derived or non–protein-containing synthetic products. Animal-derived surfactants contain variable amounts of surfactant apoproteins, whereas the older-generation synthetic products contain only phospholipids and lack surfactant proteins (SPs). Both decrease morbidity and mortality rates associated with respiratory distress syndrome (RDS) among preterm infants, compared with placebo. However, excess mortality rates have been observed with non–protein-containing synthetic surfactants, compared with the animal-derived products. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved with the addition of peptides that are functional analogs of SPs. Lucinactant is a new synthetic peptide-containing surfactant that contains sinapultide, a novel, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human SP-B. It is completely devoid of animal-derived components.
Objective. We hypothesized that the outcomes for premature infants treated with lucinactant and poractant alfa would be similar. Therefore, we compared lucinactant (Surfaxin; Discovery Laboratories, Doylestown, PA) with porcine-derived, poractant alfa (Curosurf; Chiesi Farmaceutici, Parma, Italy) in a trial to test for noninferiority.
Methods. A total of 252 infants born between 24 and 28 weeks of completed gestation, with birth weights between 600 and 1250 g, were assigned randomly in a multicenter, multinational, noninferiority, randomized, controlled study to receive either lucinactant (n = 124) or poractant alfa (n = 128) within 30 minutes of life. The primary outcome was the incidence of being alive without bronchopulmonary dysplasia (BPD) through 28 days of age. Key secondary outcomes included death at day 28 and 36 weeks postmenstrual age (PMA), air leaks, neuroimaging abnormalities, and other complications related to either prematurity or RDS. An independent, international, data and safety monitoring committee monitored the trial.
Results. The treatment difference between lucinactant and poractant alfa for survival without BPD through 28 days was 4.75% (95% confidence interval [CI]: –7.3% to 16.8%) in favor of lucinactant, with the lower boundary of the 95% CI for the difference, ie, –7.3%, being greater than the prespecified noninferiority margin of –14.5%. At 28 days, 45 of 119 infants given lucinactant were alive without BPD (37.8%; 95% CI: 29.1–46.5%), compared with 41 of 124 given poractant alfa (33.1%; 95% CI: 24.8–41.3%); at 36 weeks PMA, the rates were 64.7% and 66.9%, respectively. The corresponding mortality rate through day 28 for the lucinactant group was lower than that for the poractant alfa group (11.8% [95% CI: 6.0–17.6%] vs 16.1% [95% CI: 9.7–22.6%]), as was the rate at 36 weeks PMA (16% and 18.5%, respectively). There were no differences in major dosing complications. In addition, no significant differences were observed in the incidences of common complications of prematurity, including intraventricular hemorrhage (grades 3 and 4) and cystic periventricular leukomalacia (lucinactant: 14.3%; poractant alfa: 16.9%).
Conclusions. Lucinactant and poractant alfa were similar in terms of efficacy and safety when used for the prevention and treatment of RDS among preterm infants. The ability to enhance the performance of a synthetic surfactant with the addition of a peptide that mimics the action of SP-B, such as sinapultide, brings potential advantages to exogenous surfactant therapy.
Key Words: surfactant protein-B • lucinactant • poractant alfa • bronchopulmonary dysplasia • respiratory distress syndrome • KL4
Abbreviations: RDS, respiratory distress syndrome • BPD, bronchopulmonary dysplasia • PMA, postmenstrual age • SP, surfactant protein • CI, confidence interval
Accepted Dec 2, 2004.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Lenney, A. L. Boner, L. Bont, A. Bush, K-H. Carlsen, E. Eber, B. Fauroux, M. Gotz, A. Greenough, J. Grigg, et al. Medicines used in respiratory diseases only seen in children Eur. Respir. J., September 1, 2009; 34(3): 531 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D G Sweet and H L Halliday The use of surfactants in 2009 Arch. Dis. Child. Ed. Pract., June 1, 2009; 94(3): 78 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhandari and V. Bhandari Pitfalls, Problems, and Progress in Bronchopulmonary Dysplasia Pediatrics, June 1, 2009; 123(6): 1562 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laughon, C. Bose, F. Moya, J. Aschner, S. M. Donn, C. Morabito, J. J. Cummings, R. Segal, C. Guardia, G. Liu, et al. A Pilot Randomized, Controlled Trial of Later Treatment With a Peptide-Containing, Synthetic Surfactant for the Prevention of Bronchopulmonary Dysplasia Pediatrics, January 1, 2009; 123(1): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Lal and S. K. Sinha Review: Surfactant respiratory therapy using Surfaxin/sinapultide Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 339 - 344. [Abstract] [PDF]
|
|
|
|
|
|
F. Moya, S. Sinha, and R. B. D'Agostino Sr Surfactant-Replacement Therapy for Respiratory Distress Syndrome in the Preterm and Term Neonate: Congratulations and Corrections Pediatrics, June 1, 2008; 121(6): 1290 - 1291. [Full Text] [PDF]
|
|
|
|
|
|
W. A. Engle and A. R. Stark Surfactant-Replacement Therapy for Respiratory Distress Syndrome in the Preterm and Term Neonate: Congratulations and Corrections: In Reply Pediatrics, June 1, 2008; 121(6): 1291 - 1292. [Full Text] [PDF]
|
|
|
|
|
|
W. A. Engle and and the Committee on Fetus and Newborn Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate Pediatrics, February 1, 2008; 121(2): 419 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Lavin Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates Pediatrics, November 1, 2007; 120(5): 1223 - 1224. [Full Text] [PDF]
|
|
|
|
|
|
S. Senn, M. Costantini, and G. Rizzi Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates Pediatrics, November 1, 2007; 120(5): 1224 - 1225. [Full Text] [PDF]
|
|
|
|
|
|
F. Moya, S. Sinha, and R. B. D'Agostino Sr Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates: In Reply Pediatrics, November 1, 2007; 120(5): 1225 - 1226. [Full Text] [PDF]
|
|
|
|
|
|
F. Moya, S. Sinha, J. Gadzinowski, R. D'Agostino, R. Segal, C. Guardia, J. Mazela, G. Liu, and on behalf of the SELECT and STAR Study Investigato One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials Pediatrics, June 1, 2007; 119(6): e1361 - e1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gastiasoro-Cuesta, F. J. Alvarez-Diaz, C. Rey-Santano, A. Arnaiz-Renedo, B. Loureiro-Gonzalez, and A. Valls-i-Soler Acute and Sustained Effects of Lucinactant Versus Poractant-{alpha} on Pulmonary Gas Exchange and Mechanics in Premature Lambs With Respiratory Distress Syndrome Pediatrics, February 1, 2006; 117(2): 295 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Moya, S. K. Sinha, and R. D'Agostino Surfactant Trials Pediatrics, January 1, 2006; 117(1): 245 - 247. [Full Text] [PDF]
|
|
|
|
|
|
F. R. Moya, J. Gadzinowski, E. Bancalari, V. Salinas, B. Kopelman, A. Bancalari, M. K. Kornacka, T. A. Merritt, R. Segal, C. J. Schaber, et al. A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants Pediatrics, April 1, 2005; 115(4): 1018 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kattwinkel Synthetic Surfactants: The Search Goes on Pediatrics, April 1, 2005; 115(4): 1075 - 1076. [Full Text] [PDF]
|
|
